Burning Rock to Present Data on Its Early Detection ELSA-seq at ESMO Asia Virtual Congress 2020
20 oct. 2020 21h30 HE
|
Burning Rock Biotech Limited
GUANGZHOU, China, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that new data for its early detection ELSA-seq test...
Provectus Biopharmaceuticals Highlights Stage IV M1c Patient Outcome from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020
21 sept. 2020 12h45 HE
|
Provectus Biopharmaceuticals Inc.
Near-resolution of tumor burden, including extensive visceral hepatic diseaseExpanded data set of trial subject provided KNOXVILLE, TN, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT)...
Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
21 sept. 2020 10h20 HE
|
Genmab A/S
Media Release COPENHAGEN, Denmark and BOTHELL, Wash., 21 September 2020 Data featured in late-breaking proffered paper oral presentation Biologics license application submission planned to support...
MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020
20 sept. 2020 09h10 HE
|
MacroGenics, Inc.
MGD019 well-tolerated with early signals of activity in advanced solid tumors not typically responsive to checkpoint inhibitionRecommended Phase 2 dose established for MSS CRC, NSCLC expansion...
HalioDx contribution to precision medicine at ESMO 2020
18 sept. 2020 08h10 HE
|
HalioDx
HalioDx contribution to precision medicine at ESMO 2020 Marseille, France, September 18, 2020 HalioDx SAS, the immuno-oncology diagnostic company, today announced that, at the European Society of...
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020
18 sept. 2020 03h05 HE
|
Autolus Therapeutics plc
- AUTO3 shows promise of a highly differentiated product profile Conference call and webcast to be held Friday, September 18, 2020 at 8:00 am EDT / 1:00 pm BST LONDON, Sept. 18, 2020 (GLOBE...
Amunix to Present Preclinical Data on Protease-Activated HER2- and EGFR-Targeted T Cell Engagers at ESMO Virtual Congress 2020
17 sept. 2020 07h00 HE
|
Amunix Pharmaceuticals, Inc.
– Data demonstrate potential of Amunix’s XPAT platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treating solid tumors – – Masked prodrug...
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
17 sept. 2020 06h30 HE
|
Checkpoint Therapeutics, Inc
51.4% objective response rate and 13.5% complete response rate in half the planned pivotal cohortInterim results presented at ESMO Virtual Congress 2020On track to report full top-line results in...
Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
15 sept. 2020 07h18 HE
|
Idera Pharmaceuticals, Inc.
Final data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presentedAbbVie to present a trial-in-progress poster of ABBV-368...
Autolus Therapeutics to host Investor Conference Call to discuss AUTO3 data presented at ESMO and to participate in Banking conferences through September
08 sept. 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...